BioSante Pharmaceuticals, Inc. (BPAX)

[Just the facts maam]

I am pretty confident you won't have to wait 4 years to take a good profit. But if the company is not bought out you may want to keep your toe in the water with some of your shares for the Cancer vaccine ride.

Aduro's phase II trials of GVAX pancreas has an estimated completion date October 2014. The Chronic Myeloid Leukemia (CML) and Acute Myeloid Leukemia (AML) — Phase II trials complete they are waiting a partner to go to Phase III. They have also move forward on melenoma and breast cancer through the out-licensing through John Hopkins

GVAX out-license.

I have seen a number of companies with a market cap in excess of $500 million with one drug in Phase III trial an nothing to speak of in the pipeline.

Take a look at Dendreon Market Cap $2.11 billion. If GVAX is successful. It could be lights out for Dendreon as Gvax can be mass produced. Which means a higher profit margin while providing a product at a lower price.

Biosante could be a very interesting company in 4 to 6 years. The pipeline is shaping up like a set of dominoes. When one gets across the finish line the others will probably follow one after the other just like falling dominoes.

While you are waiting for the cancer vaccines to move forward there is The Pill Plus to keep us entertained.

From a project management standpoint, this company is well set up for continuous movement and progress.

Long term, if BPAX is not bought out and healthy revenue has started to accumulate, I wouldn't be surprised if they went after a marketing and distribution company to take the company to the next level. They will have a very good R&D program, an extremely good patent portfolio (ranked in the top 15 in 2010.) They will have experience in taking 3-4 drugs through FDA approval. The marketing arm will allow them to maximize profits and really lift the value of the company.